Profusa Amends Acquisition Agreement, Eliminating 12% Management Share Issuance
Summary
Profusa amended its acquisition agreement for the PanOmics Assay, removing a provision for a 12% management share issuance, which significantly reduces potential future dilution for shareholders.
Key Events
-
Acquisition Agreement Amended
Profusa, Inc. entered into a First Amendment to the Asset Purchase Agreement with Bio Insights LLC, originally dated April 21, 2026, for the acquisition of PanOmics Assay know-how.
-
12% Management Share Issuance Removed
The amendment deletes Section 4.6 of the original agreement, which previously provided for the issuance of common stock equal to 12% of the fully diluted shares to the CEO and CFO for retention purposes following the closing of the acquisition and any related equity financing.
-
Reduced Future Dilution
The removal of this provision significantly reduces the potential for future dilution for existing shareholders, improving the terms of the $30 million acquisition which is to be satisfied through convertible preferred stock.
Analysis
Profusa amended its Asset Purchase Agreement with Bio Insights LLC, removing a provision that would have issued common stock equal to 12% of the fully diluted shares to management post-acquisition. This is a significant positive development for existing shareholders, as it substantially reduces potential future dilution related to the $30 million PanOmics Assay acquisition. Given Profusa's ongoing financial distress, delisting threats, and previous highly dilutive financing activities, the elimination of this large share issuance improves the terms of the acquisition for current investors.
At the time of this filing, PFSA was trading at $0.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.36 to $975.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.